Clinical Trial Update: Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial of Humacyte Acellular Tissue Engineered Vessel (ATEV) for vascular trauma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trauma
• Vascular System Injury

Drugs mentioned

• Humacyte Acellular Tissue Engineered Vessel (ATEV) (Acellular Tissue Engineered Vessel)

Snippet

Sponsor: Humacyte, Inc. | Conditions: Trauma, Vascular System Injury | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-07-29